412
Views
48
CrossRef citations to date
0
Altmetric
Other Respiratory Disorders

Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis

, MSc, , PhD, , MSc, , PhD, , MSc, , MSc & , PhD show all
Pages 960-964 | Received 16 Jan 2013, Accepted 30 Jun 2013, Published online: 16 Aug 2013
 

Abstract

Objective: To investigate the expression of serum miRNA-21(miR-21) and miRNA-155 (miR-155) in idiopathic pulmonary fibrosis (IPF). Methods: A study including 65 patients with IPF and 65 similar age and gender healthy controls was performed. Serum specimens were collected from all subjects. Total RNA was extracted and the quantitative reverse transcription-polymerase chain reaction was used to measure serum miR-21 and miR-155 in both groups. Clinicopathologic features were assessed to determine associations with serum miR-21 and miR-155 concentrations. Results: Serum miR-21 expression was significantly higher in IPF samples than in healthy controls (p < 0.01), while serum miR-155 expression did not show a statistically significant difference (p > 0.05). Forced vital capacity (FVC) and radiologic features were associated with miR-21 and miR-155 expression in serum (p < 0.05). Neither miR-21 nor miR-155 expression was statistically significantly associated with clinicopathologic parameters, such as gender (p > 0.05) and age (p > 0.05). Conclusion: These findings suggest that serum miR-21 is associated with IPF and the degree of damage indicated by FVC and radiologic examinations could correlate with miR-21 and miR-155 expression in serum. From another perspective, our study confirmed serum miRNA can be stable and detectable in serum of patients with IPF, which could prove useful as it could be considered as a new biomarker in serum for diagnosis and assessment of prognosis of IPF in the future.

Acknowledgements

The authors are grateful to all staff at the study centre (the First Affiliated Hospital of Zhengzhou University and Preclinical Medicine of Zhengzhou University) who contributed to this study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.